![Sputnik V on X: "Canadian real-world study of mRNA vaccines efficiency vs # Omicron shows negative efficacy of 2 mRNA doses and quickly waning efficiency of homologous #mRNA booster: “A third dose provides Sputnik V on X: "Canadian real-world study of mRNA vaccines efficiency vs # Omicron shows negative efficacy of 2 mRNA doses and quickly waning efficiency of homologous #mRNA booster: “A third dose provides](https://pbs.twimg.com/media/FIPiC5yXoAYJFaO.jpg)
Sputnik V on X: "Canadian real-world study of mRNA vaccines efficiency vs # Omicron shows negative efficacy of 2 mRNA doses and quickly waning efficiency of homologous #mRNA booster: “A third dose provides
![mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant - ScienceDirect mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0092867421014963-fx1.jpg)
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant - ScienceDirect
![Responding to Omicron: Aggressively Increasing Booster Vaccinations Now Could Prevent Many Hospitalizations and Deaths | Commonwealth Fund Responding to Omicron: Aggressively Increasing Booster Vaccinations Now Could Prevent Many Hospitalizations and Deaths | Commonwealth Fund](https://www.commonwealthfund.org/sites/default/files/responding-to-omicron-aggressively-increasing-booster-vaccinations-now-could-prevent-many-hospitalizations-and-deaths-exhibit-2.png)
Responding to Omicron: Aggressively Increasing Booster Vaccinations Now Could Prevent Many Hospitalizations and Deaths | Commonwealth Fund
![Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/figures/mm7118a4-F-large.gif?_=74292)
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR
![Vaccines | Free Full-Text | COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects Vaccines | Free Full-Text | COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects](https://www.mdpi.com/vaccines/vaccines-10-01223/article_deploy/html/images/vaccines-10-01223-g001.png)
Vaccines | Free Full-Text | COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
Eric Topol on X: "First data on booster vaccine effectiveness vs Omicron (581 cases): drop in protection vs symptomatic infection by 2 doses (AZ ->0, Pfizer-> <40%) restored to ~75% with 3rd
![Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/91d19b8e-2f0b-4e13-8d9b-69e012d37e25/gr1.jpg)
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases
![Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What](https://www.mdpi.com/vaccines/vaccines-10-01924/article_deploy/html/images/vaccines-10-01924-g001.png)
Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What
Eric Topol on X: "The decline of vaccine effectiveness vs Omicron. Simplified (no 95% CI) summary for Pfizer vaccine vs Delta, + booster, and vs Omicron, + booster (early @UKHSA data) vs
![Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil | Nature Communications Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-33169-0/MediaObjects/41467_2022_33169_Fig1_HTML.png)
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil | Nature Communications
![Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ... Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...](https://www.cdc.gov/mmwr/volumes/72/wr/social-media/mm7205e1_BivalentVECurrentSublineages_IMAGE_25Jan2023_1200x675-medium.jpg?_=95835)